LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung

被引：0

作者：

Wu, Yi-Long ^{[1
,2
]}

Zhou, Caicun ^{[3
]}

Hu, Cheng-Ping ^{[4
]}

Feng, Jifeng ^{[5
]}

Lu, Shun ^{[6
]}

Huang, Yunchao ^{[7
]}

Li, Wei ^{[8
]}

Hou, Mei ^{[9
]}

Shi, Jian Hua ^{[10
]}

Lee, Kye Young ^{[11
]}

Massey, Dan ^{[12
]}

Shi, Yang ^{[13
]}

Chen, JiongJie Jack ^{[13
]}

Zazulina, Victoria ^{[12
]}

Geater, Sarayut L. ^{[14
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China

[4] Cent S Univ, Xiangya Hosp, Dept Pulm Med, Changsha, Hunan, Peoples R China

[5] Jiangsu Prov Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai 200030, Peoples R China

[7] Kunming Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Yunnan Tumor Hosp, Kunming, Yunnan Province, Peoples R China

[8] Jilin Univ, Hosp 1, Ctr Canc, Changchun 130023, Peoples R China

[9] Sichuan Univ, West China Hosp, Chengdu 610064, Sichuan, Peoples R China

[10] Lin Yi Tumor Hosp, Linyi, Shandong, Peoples R China

[11] Konkuk Univ, Med Ctr, Lung Canc Ctr, Seoul, South Korea

[12] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[13] Boehringer Ingelheim Int Trading Shanghai Co Ltd, Shanghai, Peoples R China

[14] Prince Songkla Univ, Fac Med, Dept Internal Med, Div Resp & Resp Crit Care Med, Hat Yai, Thailand

来源：

EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷

关键词：

Lung cancer / Oncology;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

5470

引用

页数：2

共 50 条

[21] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
Park, K.
Tan, E. H.
Zhang, L.
Hirsh, V.
O'Byrne, K.
Boyer, M.
Yang, J. C-H.
Mok, T.
Lee, K. H.
Lu, S.
Shi, Y.
Kim, S-W.
Laskin, J.
Kim, D-W.
Laurie, S. A.
Kolbeck, K.
Fan, J.
Dodd, N.
Maerten, A.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2016, 27
[22] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
Wehler, T.
Wehler, B.
Atmaca-Dirik, H.
Schulz, C.
Grohe, C.
Topsch, J.
Ehrlich, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
[23] First-line afatinib in patients with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trials
Schuler, M.
Paz-Ares, L.
Sequist, L. V.
Sebastian, M.
Wu, Y. -L.
Geater, S. L.
Maerten, A.
Fan, J.
Park, K.
Yang, J. C. -H.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 172 - 172
[24] Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
De Marinis, F.
Laktionov, K. K.
Poltoratskiy, A.
Egorova, I.
Hochmair, M.
Passaro, A.
Migliorino, M. R.
Metro, G.
Gottfried, M.
Tsoi, D.
Ostoros, G.
Rizzato, S.
Mukhametshina, G. Z.
Schumacher, M.
Novello, S.
Dziadziuszko, R.
Tang, W.
Clementi, L.
Cseh, A.
Kowalski, D.
ANNALS OF ONCOLOGY, 2019, 30
[25] Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7
Park, Keunchil
Tan, Eng Huat
Zhang, Li
Hirsh, Vera
O'Byrne, Ken
Boyer, Michael
Yang, James Chih-Hsin
Mok, Tony
Peil, Barbara
Maerten, Angela
Paz-Ares, Luis
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1214
[26] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
Park, K.
Tan, E. -H.
Zhang, L.
Hirsh, V.
O'Byrne, K.
Boyer, M.
Yang, J.
Mok, T.
Kim, M.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
[27] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
Halmos, Balazs
Tan, Eng-Huat
Lee, Min Ki
Foucher, Pascal
Hsia, Te-Chun
Hochmair, Maximilian J.
Griesinger, Frank
Hida, Toyoaki
Kim, Edward S.
Melosky, Barbara L.
Maerten, Angela
Costa, Enric Carcereny
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Yang, James Chih-Hsin
Wu, Yi-Long
Schuler, Martin
Sebastian, Martin
Popat, Sanjay
Yamamoto, Nobuyuki
Zhou, Caicun
Hu, Cheng-Ping
O'Byrne, Kenneth
Feng, Jifeng
Lu, Shun
Huang, Yunchao
Geater, Sarayut L.
Lee, Kye Young
Tsai, Chun-Ming
Gorbunova, Vera
Hirsh, Vera
Bennouna, Jaafar
Orlov, Sergey
Mok, Tony
Boyer, Michael
Su, Wu-Chou
Lee, Ki Hyeong
Kato, Terufumi
Massey, Dan
Shahidi, Mehdi
Zazulina, Victoria
Sequist, Lecia V.
LANCET ONCOLOGY, 2015, 16 (02): : 141 - 151
[29] ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
Yang, J. C.
Schuler, M.
Yamamoto, N.
O'Byrne, K. J.
Hirsh, V.
Mok, T. S. K.
Massey, D.
Zazulina, V.
Shahidi, M.
Sequist, L. V.
ANNALS OF ONCOLOGY, 2012, 23 : 410 - 411
[30] Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
Yang, James Chih-Hsin
Hirsh, Vera
Schuler, Martin
Yamamoto, Nobuyuki
O'Byrne, Kenneth J.
Mok, Tony S. K.
Zazulina, Victoria
Shahidi, Mehdi
Lungershausen, Juliane
Massey, Dan
Palmer, Michael
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3342 - +

← 1 2 3 4 5 →